KR20060130077A - 메티오닌 아미노펩티다제-2 의 저해제 및 이의 용도 - Google Patents

메티오닌 아미노펩티다제-2 의 저해제 및 이의 용도 Download PDF

Info

Publication number
KR20060130077A
KR20060130077A KR1020067012422A KR20067012422A KR20060130077A KR 20060130077 A KR20060130077 A KR 20060130077A KR 1020067012422 A KR1020067012422 A KR 1020067012422A KR 20067012422 A KR20067012422 A KR 20067012422A KR 20060130077 A KR20060130077 A KR 20060130077A
Authority
KR
South Korea
Prior art keywords
substituted
compound
unsubstituted
subject
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020067012422A
Other languages
English (en)
Korean (ko)
Inventor
찰스 톰슨
크리스토퍼 시 아리코-뮌델
Original Assignee
프래시스 파마슈티컬즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프래시스 파마슈티컬즈 인코포레이티드 filed Critical 프래시스 파마슈티컬즈 인코포레이티드
Publication of KR20060130077A publication Critical patent/KR20060130077A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/14—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
KR1020067012422A 2003-12-29 2004-12-29 메티오닌 아미노펩티다제-2 의 저해제 및 이의 용도 Withdrawn KR20060130077A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53343103P 2003-12-29 2003-12-29
US?60/533,431? 2003-12-29

Publications (1)

Publication Number Publication Date
KR20060130077A true KR20060130077A (ko) 2006-12-18

Family

ID=34748901

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067012422A Withdrawn KR20060130077A (ko) 2003-12-29 2004-12-29 메티오닌 아미노펩티다제-2 의 저해제 및 이의 용도

Country Status (9)

Country Link
US (1) US20050239878A1 (cg-RX-API-DMAC7.html)
EP (1) EP1699812A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007537147A (cg-RX-API-DMAC7.html)
KR (1) KR20060130077A (cg-RX-API-DMAC7.html)
CN (1) CN1902215A (cg-RX-API-DMAC7.html)
AU (1) AU2004312512A1 (cg-RX-API-DMAC7.html)
CA (1) CA2550873A1 (cg-RX-API-DMAC7.html)
NO (1) NO20062812L (cg-RX-API-DMAC7.html)
WO (1) WO2005066197A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
JP4514455B2 (ja) * 2002-04-11 2010-07-28 チルドレンズ メディカル センター コーポレーション Tnp−470ポリマー複合体及びその使用
WO2007124005A2 (en) * 2006-04-18 2007-11-01 Praecis Pharmaceuticals Incorporated Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors
WO2008066641A2 (en) * 2006-11-06 2008-06-05 Praecis Pharmaceuticals Incorporated Methods for treating mitf associated diseases by the use of methionine aminopeptidase-2 inhibitors
JP2010531896A (ja) * 2007-06-26 2010-09-30 チルドレンズ メディカル センター コーポレーション 治療的投与のためのMetAP−2阻害剤ポリマーソーム
EP2317845A4 (en) * 2008-07-18 2011-11-09 Zafgen Inc METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
WO2011044506A2 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
BR112012016793A2 (pt) 2010-01-08 2018-07-31 Zafgen Corp compostos tipo fumagilol e métodos de fazer e usar os mesmos
US20130023513A1 (en) 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
BR112013001613A2 (pt) 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
WO2012064928A1 (en) 2010-11-10 2012-05-18 Zafgen Corporation Methods and compositions for treating thyroid hormone related disorders
US20130316994A1 (en) 2010-11-29 2013-11-28 Zafgen, Inc. Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
JP2013543899A (ja) 2010-11-29 2013-12-09 ザフゲン,インコーポレイテッド 6−o−(4−ジメチルアミノエトキシ)シンナモイルフマギロールの非連日投与を用いた肥満の治療
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
AU2012225531B2 (en) 2011-03-08 2017-03-30 Zafgen, Inc Oxaspiro (2.5) octane derivatives and analogs
WO2012154679A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic pyrazole sulfonamide compounds and methods of making and using same
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
US9290472B2 (en) 2011-05-06 2016-03-22 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
AU2013209719A1 (en) 2012-01-18 2014-08-07 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
BR112014027808A2 (pt) 2012-05-07 2017-06-27 Zafgen Inc sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo
EP2846792B1 (en) 2012-05-08 2018-08-15 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
CN104364251B (zh) 2012-05-09 2017-02-22 扎夫根股份有限公司 烟曲霉醇型化合物及其制备和使用方法
CN104918928A (zh) 2012-11-05 2015-09-16 扎夫根股份有限公司 三环化合物及其制备方法和用途
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
KR20150126924A (ko) 2013-03-14 2015-11-13 자프겐 인크. 신장 질환 및 기타 장애의 치료 방법
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
US20200030278A1 (en) * 2017-02-10 2020-01-30 Zafgen, Inc. Pharmaceutical compositions of metap-2 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
EP0359036B1 (en) * 1988-09-01 1997-03-26 Takeda Chemical Industries, Ltd. Fumagillol derivatives
US5180738A (en) * 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
US6017954A (en) * 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
JPH06157344A (ja) * 1992-02-07 1994-06-03 Childrens Medical Center Corp:The 血管新生阻害のための医薬製剤及び血管新生阻害方法
ATE153854T1 (de) * 1992-12-16 1997-06-15 Takeda Chemical Industries Ltd Stabile pharmazeutische zubereitung mit fumagillolderivaten
FR2733498B1 (fr) * 1995-04-27 1997-05-30 Adir Nouveaux composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1998056372A1 (en) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
US6548477B1 (en) * 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6919307B2 (en) * 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis

Also Published As

Publication number Publication date
EP1699812A2 (en) 2006-09-13
JP2007537147A (ja) 2007-12-20
NO20062812L (no) 2006-07-21
WO2005066197A2 (en) 2005-07-21
CN1902215A (zh) 2007-01-24
AU2004312512A1 (en) 2005-07-21
US20050239878A1 (en) 2005-10-27
CA2550873A1 (en) 2005-07-21
WO2005066197A3 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
US20050239878A1 (en) Inhibitors of methionine aminopeptidase-2 and uses thereof
JP4212356B2 (ja) 血管新生を調節するための治療薬およびその使用方法
US6548477B1 (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
JPH09500087A (ja) カルパイン活性の増大に関連した健康障害の抑制及び処置におけるカルパイン阻害剤の使用法
AU2002239479A1 (en) Peptides as Met-AP2 inhibitors
RO119413B1 (ro) Derivaţi izosteri ai substratului aspartat proteazei, sărurile lor, compoziţii farmaceutice şi utilizare
EP0288176A1 (en) Tyrosine derivatives and use thereof
US7951780B2 (en) Antitumor agent
KR20050009702A (ko) 메티오닌 아미노펩티다제-2 저해제 및 이의 이용방법
US10344001B2 (en) Azolylacryloyl derivatives as therapeutic agents for sickle cell disease
US7098186B2 (en) Depsipeptide compound
EA019738B1 (ru) Профилактическое/терапевтическое средство против рака
US20050282741A1 (en) Peptides and their use to ameliorate cell death
CN114699401A (zh) 异鼠李素在制备胸主动脉血管舒张药物中的用途
CN106995368B (zh) 一种非atp竞争性fgfr1抑制剂及其应用
KR100450578B1 (ko) 엔엠23 단백질을 유효성분으로 하는, 매트릭스메탈로프로테아제 활성 억제 및 혈관신생 억제용 조성물
WO2023160112A1 (zh) 嗜氮酮类化合物及其在制备抗肿瘤药物中的用途
MXPA06007365A (es) Inhibidores de metionina aminopeptidasa-2 y usos de los mismos
US6365610B1 (en) Ozonide compounds with inhibitory activity for urokinase production and angiogenesis
CN113912594A (zh) 硝基噻吩甲胺类光学异构体及其医药用途
CN111320662A (zh) 一类n-苄基取代的二脒那秦衍生物及其药物用途
CN116850187A (zh) Hapalindole在制备抑制肝癌或乳腺癌的药物中的应用
EP0372410A2 (en) Use of heterocyclic amides to inhibit tumor metastasis
CN119367338A (zh) 天然产物苏木查尔酮作为成纤维细胞激活蛋白抑制剂的应用
WO2005003076A1 (en) Novel heptatrienoic acid substitued bicyclic ketone derivative and pharmaceutical compositions comprising the same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060622

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid